Evidence map›Paper›PMID 34764369›Full record

ArticleScientific reports2021

Antibody-guided design and identification of CD25-binding small antibody mimetics using mammalian cell surface display.

Kyra See, Tetsuya Kadonosono, Kotaro Miyamoto, Takuya Tsubaki, Yumi Ota, Marina Katsumi, Sumoe Ryo, Kazuki Aida, Misa Minegishi, Tatsuhiro Isozaki and 2 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Kyra SeeSchool of Life Science and Technology, Tokyo Institute of Technology, Yokohama, 226-8501, Japan.
Tetsuya KadonosonoSchool of Life Science and Technology, Tokyo Institute of Technology, Yokohama, 226-8501, Japan. tetsuyak@bio.titech.ac.jp.
Kotaro MiyamotoSchool of Life Science and Technology, Tokyo Institute of Technology, Yokohama, 226-8501, Japan.
Takuya TsubakiSchool of Life Science and Technology, Tokyo Institute of Technology, Yokohama, 226-8501, Japan.
Yumi OtaSchool of Life Science and Technology, Tokyo Institute of Technology, Yokohama, 226-8501, Japan.
Marina KatsumiSchool of Life Science and Technology, Tokyo Institute of Technology, Yokohama, 226-8501, Japan.
Sumoe RyoSchool of Life Science and Technology, Tokyo Institute of Technology, Yokohama, 226-8501, Japan.
Kazuki AidaSchool of Life Science and Technology, Tokyo Institute of Technology, Yokohama, 226-8501, Japan.
Misa MinegishiSchool of Life Science and Technology, Tokyo Institute of Technology, Yokohama, 226-8501, Japan.
Tatsuhiro IsozakiSchool of Life Science and Technology, Tokyo Institute of Technology, Yokohama, 226-8501, Japan.
Takahiro KuchimaruCenter for Molecular Medicine, Jichi Medical University, Tochigi, 329-0498, Japan.
Shinae Kizaka-KondohSchool of Life Science and Technology, Tokyo Institute of Technology, Yokohama, 226-8501, Japan.
Tokyo Institute of Technology · JPJichi Medical University · JP

Funding

Japan Agency for Medical Research and Development JP19ak0101098h0002
6 · The paper itself

Abstract

Small antibody mimetics that contain high-affinity target-binding peptides can be lower cost alternatives to monoclonal antibodies (mAbs). We have recently developed a method to create small antibody mimetics called FLuctuation-regulated Affinity Proteins (FLAPs), which consist of a small protein scaffold with a structurally immobilized target-binding peptide. In this study, to further develop this method, we established a novel screening system for FLAPs called monoclonal antibody-guided peptide identification and engineering (MAGPIE), in which a mAb guides selection in two manners. First, antibody-guided design allows construction of a peptide library that is relatively small in size, but sufficient to identify high-affinity binders in a single selection round. Second, in antibody-guided screening, the fluorescently labeled mAb is used to select mammalian cells that display FLAP candidates with high affinity for the target using fluorescence-activated cell sorting. We demonstrate the reliability and efficacy of MAGPIE using daclizumab, a mAb against human interleukin-2 receptor alpha chain (CD25). Three FLAPs identified by MAGPIE bound CD25 with dissociation constants of approximately 30 nM as measured by biolayer interferometry without undergoing affinity maturation. MAGPIE can be broadly adapted to any mAb to develop small antibody mimetics.

Indexed as

Amino Acid SequenceAnimalsAntibodies, MonoclonalAntibody AffinityCell LineCell Line, TumorCell Surface Display TechniquesFlow CytometryHEK293 CellsHeLa CellsHumansInterleukin-2 Receptor alpha SubunitK562 CellsMammalsPeptide LibraryProtein BindingAntibodies, MonoclonalIL2RA protein, humanInterleukin-2 Receptor alpha SubunitPeptide Library

Identifiers

PMID34764369
PMCPMC8585965
OpenAlexW3213743590

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.